Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Akero Therapeutics Shares Surge After Equity Investment From This Famed Large Cap Biopharma

Akero Therapeutics Inc (NASDAQ:AKRO) announced a $25 million equity investment by Pfizer Inc (NYSE:PFE) at $9.90 per share. The company also announced a term loan facility providing Akero with access to up to $100 million from Hercules Capital Inc (NYSE:HTGC), of which $10 million will be drawn at transaction close. Together with existing cash, proceeds will support…

Benzinga

A major pandemic hurdle is being crossed with young kids getting vaccine access

Parents of infants and toddlers are a major step closer to having front-line protection against COVID after a key FDA committee on Wednesday unanimously recommended authorizing vaccines for kids as young as six months.

Axios

US FDA panel backs first Covid-19 jabs for children under five

The first COVID-19 shots for U.S. infants, toddlers and preschoolers moved a step closer Wednesday.

France 24

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA panel recommends COVID vaccines for little kids, but questions remain about where they’ll be available

CHICAGO — Mary MacMillan is eager to get her 2-year-old son vaccinated against COVID-19, once vaccines are authorized for young kids. But she has a lot of questions about how to get the shots.

Chicago Tribune

FDA panel gives green light to pediatric COVID-19 vaccines - Roll Call

Those under 5 are the last group eligible for the Moderna and Pfizer vaccines, and shots could go out as soon as next week.

Roll Call

America's FDA panel backs Moderna and Pfizer COVID-19 vaccines for children under five. Here's what that means

Advisors to US federal regulators are backing two COVID-19 vaccines for children as young as six months old, with the final decision to be watched closely by Australian health officials, along with parents eager to put pandemic concerns behind them.

ABC News

Moderna’s COVID shot for youngest children gets FDA panel’s support

Moderna Inc.’s COVID-19 vaccine for infants and toddlers won the support of a panel of U.S. regulatory advisers, putting parents one step closer to being able to protect their youngest against COVID-19 for the first time.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

FDA just authorized Covid-19 vaccines for kids under 5. Here’s what parents need to know

An outside panel of experts for the FDA recommended both the Moderna and Pfizer vaccine for kids under 5. Shortly after, the FDA granted a EUA.

Inverse

FDA committee recommends COVID shots for kids as young as 6 months

Children younger than 5 are the last group without access to the shots.

Axios

Access, hesitancy loom over COVID-19 vaccine rollout for toddlers - Roll Call

Adults had plenty of opportunities to get their COVID-19 vaccines. But it won't be as easy for those under age of 5.

Roll Call

FDA advisers weigh COVID-19 shots for babies, young children

U.S. government advisers met Wednesday to decide whether to endorse COVID-19 shots for the youngest children, moving the nation closer to vaccinations for all ages

The Independent UK

The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Pfizer Halts Enrollment In Paxlovid COVID-19 Trial In Standard-Risk Population

Pfizer Inc (NYSE:PFE) shared additional data from the Phase 2/3 EPIC-SR study of Paxlovid (nirmatrelvir and ritonavir tablets) in patients at standard risk for developing severe COVID-19. In previously reported interim analyses, the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days was not met. Non-significant 70% relative…

Benzinga

What's hot in life sciences? Bio International Convention looks at what's next as pandemic recedes

It's no secret that during the COVID-19 pandemic, the global life sciences industry shined. It ramped up development of everything from diagnostic tests to new vaccines — including two based on previously unproven messenger RNA technology —all within months instead of years.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

EU Urges Pfizer To Further Delay COVID-19 Vaccine Deliveries: Reuters

Amid lower demand, Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) agreed to delay supplies of their Covid-19 shot to the European Union. Doses to be shipped from June to August would be sent in September and Q4. Reuters reports that the bloc is putting heat on Pfizer to restrict supplies further. The move comes two weeks after…

Benzinga

Moderna's COVID-19 Shot Likely Related To Higher Heart Inflammation Risk Than Pfizer's: Reuters

Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine may relate to a higher risk of heart inflammation in some age groups than Pfizer Inc (NYSE:PFE) - BioNTech SE's (NASDAQ:BNTX) shot, Reuters reported citing the Centers for Disease Control and Prevention. Citing recent data, CDC said that the findings on myocarditis and pericarditis, types of heart inflammation linked to both the…

The Independent UK

FDA advisers consider Moderna's COVID shots for older kids

A government advisory panel is meeting to decide whether to recommend a second brand of COVID-19 vaccine for school-age children and teens

Benzinga

Australia's ResApp Takeover Bid Undervalued - Read What Pfizer Did

Following an independent expert report suggesting that Australia-based ResApp Health Limited's current share price was undervalued, Pfizer Inc (NYSE: PFE) bolstered its takeover bid.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Pfizer Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 23 strange trades.

Axios

The youngest Americans may finally get their COVID shots

Regulators will evaluate both Pfizer-BioNTech and Moderna shots this week.

Tribune News Service

Pfizer COVID shot works, safe for youngest kids, FDA says

U.S. Food and Drug Administration staff said that Pfizer Inc.’s COVID-19 shot was effective for kids ages 4 and under with no new safety concerns, in a report released ahead of a key meeting of FDA advisers later this week.

The Independent UK

US: Pfizer COVID-19 appears effective for kids under 5

A review by federal health officials says that Pfizer's COVID-19 vaccine appears safe and effective for children under 5, the only group not currently eligible for vaccination

Inverse

Research on a deadly bacteria might be a COVID-19 vaccine gamechanger

The Covid-19 pandemic, being truly global, created the demand for vaccines, such as the now-familiar ones from Pfizer, Moderna and AstraZeneca.

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

1 … 48 49 50 51

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

346 stories

PFE

345 stories

Centers for Disease Control and Prevention

315 stories

Pfizer Inc

313 stories

Chicago Public Schools

295 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.